Diffuse Intrinsic Brainstem Gliomas
Conditions
Keywords
brainstem gliomas, pediatric patients
Brief summary
The study consists in only one treatment group, which will receive the first-line therapy for the disease - standard radiotherapy and a 150 mg/m2 dose of the investigational product (nimotuzumab)
Detailed description
General Purpose 1\. To determine the therapeutic efficacy of the treatment with nimotuzumab in combination with radiotherapy in pediatric patients with diffuse intrinsic astrocytic of the brainstem glioma Specific Purposes 1. To determine the efficacy regarding the event-free survival (EFS) rate by 6 months of treatment. 2. To determine the overall survival time of the patients with diffuse intrinsic astrocytic tumors of the cerebral trunk treated with combined radiotherapy and nimotuzumab. 3. To determine the antitumoral objective response of the patients treated with combined radiotherapy and nimotuzumab. 4. To determine the duration time of the response in the cases of objective response reached (CR or PR) or disease stabilization. 5. To assess the toxicity of the combination AcM h-R3-nimotuzumab and radiotherapy in the patients enrolled in the clinical study.
Interventions
RADIATIONRadiotherapy
Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
BIOLOGICALNimotuzumab
The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
Sponsors
Centro de Immunologia Molecular, Cuba
Eurofarma Laboratorios S.A.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Pediatric patients with diffuse intrinsic brainstem gliomas, documented by standard imaging techniques (MRI). Note: Tumor biopsy and histological confirmation are not required in this study. 2. Patients eligible for radiotherapy with Cobalt60. The patients should not have received a previous specific oncological treatment. 3. Aged \> 3 years old \< 18 years old 4. Patients with measurable lesions, defined as those that can be accurately measured in at least 2 dimensions (the 2 largest perpendicular diameters), using standard techniques (MRI). 5. Female patients with childbearing potential should present a negative pregnancy test and adopt effective birth control methods, in case they are sexually active. 6. Male patients who can father a child should adopt effective birth control methods, in case they are sexually active. 7. Life expectancy \> 12 weeks 8. Health general status, according to Karnofsky Index \> 40% (Karnofsky Index for patients \> 16 years old), Lansky \> 40% (for patients \< 16 years old) 9. Laboratory parameters within the normal limits, defined as: Hematopoietic: Hemoglobin \> 10 g/L, Total Leukocytes \> 2 x 109 cells/L, Platelets \> 100 x 109/L; Hepatic: Liver functioning within the normal limits and without hepatic diseases demonstrated by ALT, AST \< 2.5 x above the reference value and Total Bilirubin \< 1.5 x above the reference value; Renal function: Serum Creatinine \< 1.5 x above the reference value. 10. The parents or legal guardians should express, voluntarily, in writing, that the patient will be enrolled in the study upon signature of the informed consent form. At the investigator's discretion, where applicable, the consent will be obtained from the minor.
Exclusion criteria
1. Low-grade brainstem glioma (e.g., focal, cervicomedullary, tectal brainstem glioma). 2. Patients previously treated with some AcM. 3. Patients previously treated with some antineoplastic therapy, including chemotherapy, immunotherapy or radiotherapy. 4. Concurrent treatment with some antineoplastic therapy not conceived in the study protocol. 5. Breastfeeding or pregnant patients. 6. Patients that, at the time of enrollment, have some related chronic disease under decompensation (e.g., cardiopathy, diabetes, hypertension). 7. Patients who have history of hypersensitivity to this or another similar product. 8. Fever, severe septic processes and/or severe or acute allergy. 9. Patients who are participating in another clinical study with therapeutic purposes for their disease based on the time of the study enrollment. 10. Presence of a second tumor.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor Volume | 6 months | A Magnetic Resonance Imaging (MRI) will be used for measuring the tumor volume and it will be performed before the enrollment in the clinical study and every 12 weeks. The patient follow-up will be performed for 2 years after his/her inclusion in the investigation. The final evaluation will be performed 2 years after the inclusion of the last patient. The main response variable will be the progression-free survival by 6 months. |
Countries
Brazil, Cuba
Outcome results
None listed